Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors

Author:

Nishimura Tadashi12ORCID,Fujimoto Hajime2,Fujiwara Takumi23,Ito Kentaro4,Fujiwara Atsushi5,Yuda Hisamichi6,Itani Hidetoshi7,Naito Masahiro1,Kodama Shuji5,Furuhashi Kazuki2,Yagi Akihiko2,Saiki Haruko2,Yasuma Taro8,Okano Tomohito2,Tomaru Atsushi2,Tanigawa Motoaki7,Yoshida Masamichi5,Hataji Osamu4,Ibata Hidenori1,D'Alessandro‐Gabazza Corina N.8,Gabazza Esteban C.28ORCID,Kobayashi Tetsu2

Affiliation:

1. Department of Pulmonary Medicine Mie Chuo Medical Center Tsu Japan

2. Department of Pulmonary and Critical Care Medicine Mie University Faculty and Graduate School of Medicine Tsu Japan

3. Department of Genomic Medicine Mie University Hospital Tsu Japan

4. Respiratory Center Matsusaka Municipal Hospital Matsusaka Japan

5. Department of Pulmonary Medicine Mie Prefectural General Medical Center Yokkaichi Japan

6. Department of Pulmonary Medicine Kuwana City Medical Center Kuwana Japan

7. Department of Respiratory Medicine Ise Red Cross Hospital Ise Japan

8. Department of Immunology Mie University Faculty and Graduate School of Medicine Tsu Japan

Abstract

AbstractBackgroundImmune checkpoint inhibitors have recently become the standard of care in the first‐line treatment of extensive‐stage small cell lung cancer. Although immune‐related adverse events have been reported to influence prognosis in non‐small cell lung cancer patients, few studies have investigated the prognostic value of immune‐related adverse events in small cell lung cancer patients. In this study, we evaluated the prognosis of patients who developed immune‐related adverse events after first‐line treatment with immune checkpoint inhibitor‐based chemotherapy for extensive‐stage small cell lung cancer.MethodsWe enrolled 90 patients with extensive‐stage small cell lung cancer who received immune checkpoint inhibitor‐based chemotherapy as first‐line treatment from September 2019 to December 2022 in six hospitals in Japan. The patients were categorized into groups with and without immune‐related adverse events.ResultsThere were 23 patients with and 67 without immune‐related adverse events. Seventeen patients had grade 1–2 immune‐related adverse events, and nine (including overlapping cases) had grade ≥3. The most frequent immune‐related adverse event was a skin rash. The median survival time was 22 months in patients with immune‐related adverse events and 9.3 months in patients without immune‐related adverse events. The hazard ratio was 0.40 (95% confidence interval: 0.19–0.83, p = 0.013).ConclusionsThe results of this study show that immune‐related adverse events are associated with improved survival outcomes in patients with extensive‐stage small cell lung cancer.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3